- Home
- DRTS vs LCTX Comparison
DRTS vs LCTX Comparison
Compare DRTS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- LCTX
- Stock Information
- Founded
- DRTS 2015
- LCTX 1990
- Country
- DRTS Israel
- LCTX United States
- Employees
- DRTS N/A
- LCTX N/A
- Industry
- DRTS Medical/Dental Instruments
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DRTS Health Care
- LCTX Health Care
- Exchange
- DRTS Nasdaq
- LCTX Nasdaq
- Market Cap
- DRTS 158.4M
- LCTX 166.3M
- IPO Year
- DRTS N/A
- LCTX N/A
- Fundamental
- Price
- DRTS $2.20
- LCTX $0.92
- Analyst Decision
- DRTS Strong Buy
- LCTX Strong Buy
- Analyst Count
- DRTS 3
- LCTX 3
- Target Price
- DRTS $8.00
- LCTX $5.67
- AVG Volume (30 Days)
- DRTS 23.4K
- LCTX 464.1K
- Earning Date
- DRTS 11-22-2024
- LCTX 11-14-2024
- Dividend Yield
- DRTS N/A
- LCTX N/A
- EPS Growth
- DRTS N/A
- LCTX N/A
- EPS
- DRTS N/A
- LCTX N/A
- Revenue
- DRTS N/A
- LCTX $6,186,000.00
- Revenue This Year
- DRTS N/A
- LCTX N/A
- Revenue Next Year
- DRTS N/A
- LCTX $123.52
- P/E Ratio
- DRTS N/A
- LCTX N/A
- Revenue Growth
- DRTS N/A
- LCTX N/A
- 52 Week Low
- DRTS $1.75
- LCTX $0.77
- 52 Week High
- DRTS $3.40
- LCTX $1.61
- Technical
- Relative Strength Index (RSI)
- DRTS 44.90
- LCTX 55.63
- Support Level
- DRTS $2.20
- LCTX $0.88
- Resistance Level
- DRTS $2.30
- LCTX $0.97
- Average True Range (ATR)
- DRTS 0.08
- LCTX 0.04
- MACD
- DRTS -0.00
- LCTX 0.01
- Stochastic Oscillator
- DRTS 22.22
- LCTX 71.56
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.